Ferritin: a cytoprotective antioxidant strategem of endothelium by Balla, György et al.
THE JOURNAL OF BIOLOGICAL CHEMISTRY 
0 1992 by The American Society for  Biochemistry  and Molecular Biology, Inc. 
Vol ,267, No. 25, Issue of September 5, pp. 18148-18153,1992 
Printed in U. S. A. 
Ferritin: A Cytoprotective  Antioxidant Strategem of Endothelium* 
(Received for publication, April 3, 1992) 
Gyorgy Balla, Harry S .  Jacob, Jozsef  Balla, Mark Rosenberg, Karl  Nath,  Fred Apple, 
John W. Eaton#,  and  Gregory M. Vercellottig 
From  the  Departments of Medicine,  and  Laboratory  Medicine  and  Pathology,  University of Minnesota, 
Minneapolis,  Minnesota 55455 and the  $Department of Pathology  and  Laboratory  Medicine,  Albany  Medical College, . .  
Albany,-New  York 12208 
Phagocyte-mediated oxidant  damage  to  vascular  en- 
dothelium is likely  involved  in various vasculopathies 
including atherosclerosis and pulmonary leak syn- 
dromes  such as adult  respiratory  distress syndrome. 
We have  shown that heme, a hydrophobic iron  chelate, 
is rapidly incorporated into endothelial cells where, 
after  as  little as 1 h, it markedly  aggravates cytotox- 
icity  engendered  by  polymorphonuclear  leukocyte  ox- 
idants  or  hydrogen  peroxide  (H20z).  In  contrast, how- 
ever, if cultured endothelial cells are briefly pulsed 
with heme and  then allowed to  incubate  for  a  prolonged 
period (16 h), the cells become highly resistant  to  oxi- 
dant-mediated  injury  and  to  the  accumulation of endo- 
thelial  lipid  peroxidation  products.  This  protection is 
associated with  the induction  within 4 h of mRNAs for 
both heme oxygenase and  ferritin. After 16 h heme 
oxygenase and  ferritin  have  increased  approximately 
SO-fold and 10-fold,  respectively.  Differential  induc- 
tion of these  proteins  determined  that  ferritin s prob- 
ably  the  ultimate  cytoprotectant.  Ferritin  inhibits ox- 
idant-mediated  cytolysis  in  direct  relation  to its intra- 
cellular concentration. Apoferritin, when added to 
cultured  endothelial  cells, is taken  up  in a dose-respon- 
sive  manner  and  appears as cytoplasmic granules  by 
immunofluorescence; in a similar dose-responsive 
manner, added apoferritin protects endothelial cells 
from oxidant-mediated cytolysis. Conversely, a site- 
directed  mutant of ferritin  (heavy  chain Glu” 4 Lys; 
Hisas + Gly) which lacks  ferroxidase  activity  and is 
deficient  in iron  sequestering  capacity, is completely 
ineffectual as a  cytoprotectant. We conclude that en- 
dothelium and  perhaps  other cell types may be pro- 
tected  from  oxidant  damage  through  the  iron  seques- 
trant,  ferritin. 
Aerobic organisms are well endowed with enzymatic oxi- 
dant defense systems which protect  against  direct  assault by 
activated oxygen species such as superoxide and hydrogen 
peroxide (H202). However, much of the cellular damage 
caused by activated oxygen involves the  collaboration of in- 
tracellular iron. For example, the  amount of Hz02 required to 
kill Stuphylococcus uureus decreases  1,000-fold if the  bacteria 
R 0 1  HL33793, R32, HL28935, and R01  AI25625. The costs of 
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are  raised  in  iron-rich media (1). Conversely, iron  chelators 
such  as  deferoxamine  and dipyridyl protect eukaryotic and 
prokaryotic cells against challenge by oxidants  such  as H202 
(2, 3). This implies that oxidative reactions, when  catalyzed 
by intracellular iron, are especially potent and important 
damaging  events  and,  further,  that endogenous iron seques- 
trants  might be critical  in  antioxidant  strategy. 
Heme, a ubiquitous  iron-containing compound, is present 
in large amounts  in  many cells and  is also inherently  danger- 
ous, particularly  when  it escapes from  intracellular  sites  (4). 
Its  toxicity may  reflect the  fact  that, unlike  “free” iron,  heme 
readily enters  the hydrophobic domain of biologic membranes. 
The  vascular  endothelium, because of its  continuous  contact 
with  circulating  red blood cells, might be at  risk  from exoge- 
nous heme exposure. In previous studies we showed that 
hemin rapidly intercalates  into  cultured  endothelial cells re- 
sulting in their marked hypersusceptibility to subsequent 
oxidant-mediated cytolysis  by H202 or  adherent polymorpho- 
nuclear  leukocytes (PMNs)’ ( 5 ) .  
The foregoing considerations  prompted  us  to hypothesize 
that  endothelial cells might  synthesize a natural  iron  chelator 
to limit the reactivity of heme-derived intracellular iron. 
Within most cells the major depot of nonmetabolic iron is 
ferritin, a high molecular mass (450 kDa), multimeric (24- 
subunit)  protein (heavy or H chain M ,  21,000, light  or L chain 
M ,  20,700) with a  very  high capacity for storing  iron (4,500 
mol of iron/mol of ferritin).  In  the  ferritin shell the  proportion 
of H and L subunits  depends  on  the  iron  status of the cell or 
tissue and varies between organs and species (6). Despite 
earlier reports that under certain chemical circumstances 
ferritin can release  catalyticallyactive iron (7) which can 
actually  foster  peroxidation of lipids (8), recent  studies uggest 
that such release is slight under more physiologic circum- 
stances, less than 2 of 4,500 potential  iron  atoms released per 
ferritin molecule (9). Alternatively, ferritin  might beneficially 
sequester  intracellular  iron,  limiting  the  pro-oxidant  hazard 
posed by this reactive metal; moreover, the  fact  that  the H 
chain of ferritin  manifests ferroxidase  activity (10 , l l )  implies 
that  ferritin-stored  iron  might  resist cyclical reduction/oxi- 
dation  reactions which tend  to  propagate  and amplify  oxida- 
tive damage. 
The following studies, which  have  been presented  in  prelim- 
inary form  elsewhere (12), demonstrate  that  endothelial ex- 
posure  to  heme induces sequential  synthesis of heme oxygen- 
ase followed by ferritin; the latter whether endogenously 
produced or added directly as  the  apoprotein,  protects  endo- 
The abbreviations used are: PMN(s), polymorphonuclear leuko- 
cyte(s); H, heavy; L, light; DMEM, Dulbecco’s modified Eagle’s 
medium; FCS,  fetal calf serum; HBSS, Hanks’  balanced salt solution; 
PAEC, porcine aortic endothelial cells; Fe-PIH, iron-pyridoxal iso- 
nicotinoyl hydrazone. 
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thelium from oxidant-mediated cytolysis and does so in a 
dose-responsive manner. Using an oligonucleotide site-di- 
rected mutant of ferritin H chain, we further validate the 
critical role of the ferroxidase and iron sequestering properties 
of ferritin in this cytoprotection. 
Reagents-Dulbecco’s modified Eagle’s medium (DMEM), fetal 
calf serum (FCS) and Hank’s balanced salt solution (HBSS) were 
obtained from GIBCO, and minimal essential medium was from 
Hazleton (Lenexa, KS). Collagenase type I was purchased from 
Worthington. Heparin was obtained from Lypho-Med (Melrose Park, 
IL); hydrogen peroxide (HZ02, 30%), from Fisher Scientific; 6% 
hydroxyethyl starch, from Du Pant; deferoxamine mesylate, from 
CIBA-Geigy; and “CrO, (as the sodium salt), from Amersham Corp. 
Bovine hemin type I and tin mesoporphyrin IX were obtained from 
Porphyrin Products (Logan, UT). All other reagents utilized were 
obtained from Sigma unless otherwise specified. 
endothelial cell microsomes was measured by bilirubin generation 
(19-23). PAEC grown in IO-cm-diameter tissue culture dishes were 
treated with control media, hemin (10 FM), or other reagents as 
indicated for various time periods up to 20 h. The cells were washed, 
scraped with a rubber policeman, centrifuged at 1,000 X g for 10 min 
at 4 “C. The cell pellet was suspended in MgCl, (2 mM) phosphate 
(100 mM) buffer (pH 7.4), frozen to -70 “C, and thawed three times 
and sonicated on ice prior to centrifugation at 18,800 X g for 10 min 
at 4 “C. The supernatant was added to the reaction mixture (400 ~1) 
containing rat liver cytosol (2 mg), hemin (20 fiM), glucose 6-phos- 
EXPERIMENTAL PROCEDURES 
Endothelial Cell Isolation and Culture-As described previously (5), 
porcine aortic endothelial cells (PAEC) were isolated from porcine 
aorta using type I collagenase (0.2% for 15 min at 37 “C). Endothelial 
cells were grown in DMEM containing 10% FCS. oenicillin (100 
units/ml), streptomycin (100 units/ml); and supplemented with L- 
glutamine to confluence and used from passages 5 to 15. Human 
umbilical vein endothelial cells and human aortic endothelial cells 
were grown as described previously and utilized (13, 14). 
Human Neutrophil Preparation-As in our previous studies (15), 
neutrophils (PMNs) were isolated from human volunteers after in- 
formed consent (following guidelines of the Committee on the Use of 
Human Subjects in Research of the University of Minnesota). 
Endothelial Cytotoxicity Assays-Confluent endothelial cells (usu- 
ally PAEC) grown in 24-well (2 cm*/well) tissue culture plates were 
radiolabeled with 2 (.&i/well NaZ5iCr04 in DMEM-FCS overnight. 
The wells were washed three times with HBSS and H,O, (100 PM) or 
phorbol myristate acetate- (100 rig/ml) activated PMNs (2:l 
PMN:endothelial cell ratio) added for 2 h. Specific cytoxicity values 
were calculated as described previously (15). Spontaneous 5’Cr release 
was below 10% in all experiments. 
Endothelial Cell Treatments-We have shown previously (5) that 
pretreatment of PAEC with hemin sensitized these cells to free 
radical-mediated injury. In brief, a stock solution of 1 mM hemin was 
prepared in 10 mM NaOH and was diluted to the desired final 
concentration in DMEM. After washing, the confluent PAEC were 
incubated with hemin (5 pM) for 1 h, and at the end of this sensiti- 
zation period, the cells were washed with HBSS prior to the cytotox- 
icity assay (see above). For inducing cytoprotection against free 
radical killing, PAEC were pretreated with hemin for prolonged time 
periods (up to 16 h). This induction phase was accomplished by 
pulsing the cells with hemin (10 pM) for 60 min; the culture medium 
was then replaced with heme-free solution for 15 h (or less as 
indicated) before oxidant exposure. In some experiments, other re- 
agents were utilized during the endothelial cell induction phase. Iron- 
pyridoxal isonicotinoyl hydrazone (Fe-PIH) chelate (100 pM iron 
content) synthesized from ferric ammonium citrate, isonicotinic acid 
hydrazide, and pyridoxal hydrochloride (16, 17) was added to PAEC 
in DMEM-FCS for 16 h prior to the cytotoxicity assay. Sodium 
arsenite (50 uM) was added in DMEM for 60 min. the cells washed. 
and the culture medium replaced for 15 h prior to the killing assay. 
Tin mesoporphyrin IX (25 PM), or deferoxamine (1 mM), or cyclo- 
heximide (10 @g/ml) was each added with hemin (10 NM) during the 
endothelial cell induction phase and kept in place until the hemin 
sensitization phase. In control experiments these treatments did not 
cause cell damage except for cycloheximide, which caused approxi- 
mately 10% specific cytotoxicity. In some experiments, endothelial 
cells were loaded with horse apoferritin (0.1-2.0 mg/ml) or human 
recombinant wild type or mutant (222) H chain ferritin (1 mg/ml) (a 
gift from Drs. Hal Broxmeyer, Indiana University, and Paolo Arosio, 
Milano, Italy) for 16 h prior to the cytotoxicity assay. The mutant 
222, prepared by oligonucleotide site-directed mutagenesis and whose 
properties have been described in detail (la), has a substitution of 2 
amino acids in the H subunit. The mutation abolishes ferroxidase 
activity of the otherwise intact ferritin molecule and also differs from 
the native molecule in its poor-to-absent iron sequestrant capacity: 
thus, it fails to react with iron at acidic DH and does not facilitate 
incorporation of iron by transfected Eschbichia coli. 
Heme Oxygenuse Enzyme Actiuity-Heme oxygenase activity in 
phate (2 inM), glucose-6-phosphate dehydrogenase (0.2 units), and 
NADPH (0.8 mM) for 1 h at 37 “C in the dark. The formed bilirubin 
was extracted with chloroform and A O.D. 464-530 nm was measured 
(extinction coefficient, 40 mM-’ cm-i for bilirubin). Heme oxygenase 
activity is expressed as pmol of bilirubin formed/mg of endothelial 
cell protein/60 min. 
Ferritin Assays-Endothelial cell ferritin content was measured in 
cells grown in 3.5~cm tissue culture dishes treated with control media, 
hemin, or other reagents as indicated for various time periods up to 
20 h. At the indicated time points, the cells were solubilized with 
Triton X-100, Nonidet P-40-containing Tris-HCl buffer, pH 7.2, with 
protease inhibitors (24), centrifuged at 10,000 X g for 10 min at 4 “C, 
and the supernatant analyzed for ferritin content using the Stratus 
fluorometric enzyme immunoassay system (25). Human, horse, and 
porcine apoferritin (a kind gift from Dr. J. E. Smith, Kansas State 
University) were used as standards. The results are expressed as ng 
of ferritin/mg of endothelial cell protein. Endothelial cell ferritin was 
also demonstrated by immunofluorescent techniques in methanol- 
permeabilized and fixed human umbilical vein endothelial cells using 
a goat anti-human ferritin serum as primary antibody (ATAB, Still- 
water, MN) and a rabbit anti-goat IgG fluorescein isothiocyanate- 
labeled secondary antibody. Nonspecific goat serum or rabbit IgG 
alone served as a control. 
Heme Oxygenase and Ferritin mRNA Analysis-Heme oxygenase 
and H and L chain ferritin mRNA content were analyzed in PAEC 
grown in lo-cm tissue culture dishes after treatment with control 
media, hemin, or other reagents for various time periods. Endothelial 
cell RNA was isolated by the RNAzol method (TEL-TEST, Inc., 
Friendswood, TX). Aliquots (20 Fg) of total RNA were electropho- 
resed in a 1% agarose gel and transferred to nitrocellulose membranes 
(26). In each gel the position of the 28 and 18 S ribosomal RNA was 
determined in a separate lane by ethidium bromide staining. The size 
estimates for the signals were checked by the use of a “‘P-labeled 
DNA ladder. The membranes were then- hybridized at 42 “C with 
nick-translated “P-labeled cDNA probes for human heme oxygenase 
(27) (obtained from Dr. R. Tyrrell, Swiss Institute for Experimental 
Research, Epalinges, Switzerland) and rat H ferritin and L ferritin 
(28. 29) (obtained from Dr. H. N. Munro. Tufts Universitv. Boston. 
MA). Autoradiographs were obtained and quantified by computer: 
assisted videodensitometry (30). 
Protein and Lipid Peroxidation Assay-The protein content of the 
endothelial cell monolayers was determined using bovine serum al- 
bumin as a standard (31). Endothelial cell lipid peroxidation was 
measured using the thiobarbituric acid calorimetric assay as described 
previously (5). 
RESULTS 
As shown in Fig. 1A (and reported previously in another 
context (5)), brief (l-4 h) but not prolonged (16 h) exposure 
of porcine endothelial cells to 5 pM hemin synergizes cellular 
oxidant damage by added HZ02 (open symbols) or phorbol- 
stimulated PMNs (solid symbols) with an optimal heme- 
exposure duration of 2 h. However, if endothelial cells are 
preincubated with hemin for longer periods, cells become 
completely resistant to subsequent oxidant killing. In further 
studies which amplify this phenomenon (shown in Fig. lB), 
the cells were pulsed with a brief preincubation of hemin (10 
pM) and then washed and incubated for a further 15 h; these 
cells then resist the usually very damaging combinations of 
newly added hemin (5 pM) plus H202 (compare third and 
fourth bars) or stimulated PMNs (compare seventh and eighth 
bars). Similar results were observed when human umbilical 
vein or human aortic endothelial cells were used instead of 
porcine aortic cells (data not shown). 
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’O 1 
B 
TIME AFTER HEMIN TREATMENT (hour) 
INDUCTION - HEMIN - HEMIN - HEMIN - HEMIN 
SENSITIZATION - - Hemln  Hemln - - Hemln Hemln 
TOXICITY H202  H202  HZ02 H Z 0 2  PUN  PUN  PUN  PUN 
FIG. 1. A, time-dependent effect of hemin treatment  on hydrogen 
peroxide and activated neutrophil-mediated endothelial cell lysis. 
Confluent “Cr-labeled porcine  aortic  endothelial cells grown in 24- 
well (2 cm2/well) tissue  culture  plates were incubated  with  hemin (5 
PM) in 500-pl DMEM for 60 min (5). After removal of the hemin 
solution  the cells were cultured for the  indicated  time periods.  Before 
the killing phase,  the  endothelial cells were washed  twice with HBSS; 
H202 (100 PM) (open  squares) or PMA- (100 ng/ml)  activated  neutro- 
phils  (PMNs, 2:l PMN:endothelial cell ratio) (closed squares) were 
added to the endothelial cells  for 2 h, and the percent specific 
cytotoxicity values were calculated. Results  represent  mean f S.E. of 
live experiments performed in duplicate. B,  cytoprotection against 
hemin-catalyzed  injury of endothelial cells induced by hemin  pretreat- 
ment.  Treatment of endothelial cells  was as described under  “Exper- 
imental  Procedures” with the  indicated exception: namely that endo- 
thelial cells  were  exposed to hemin a t  two separate times. The 
induction  phase was accomplished by 10 p~ hemin treatment for 60 
min,  the  culture medium  replaced, and  the cells incubated a further 
15 h  before the  sensitization phase. Endothelial cell sensitization was 
provided by the addition of 5 PM hemin for 60 min 2 h before the 
cytotoxicity  phase  (addition of H202 or PMNs)  as described under 
“Experimental Procedures.” Results  represent  mean  percent specific 
cytotoxicity f S.E. of a t  least seven experiments  performed  in  dupli- 
cate. 
Since  incubation of hepatocytes  and  fibroblasts  with  hemin 
is known to  cause  induction of both  heme oxygenase (28,32) 
and ferritin (28, 33), we wondered whether one or both of 
these constituents might provide oxidation resistance. As 
shown in Fig. 2 A ,  porcine  aortic  endothelial cells, when  in- 
cubated with 10 p~ hemin,  are  rapidly  induced  to  synthesize 
heme oxygenase mRNA. In addition, as shown in Fig. 2B, 
light chain ferritin mRNA increases, albeit gradually. Con- 
versely, endothelial  ferritin H chain  mRNA did not  increase 
following exposure to hemin  (data  not  shown);  this coincides 
with previous studies  demonstrating  that  iron-mediated reg- 
ulation of ferritin synthesis occurs primarily by post-tran- 
scriptional/translational modulation (6,  29). An associated 
increased  synthesis of the  subsequent  intact  heme oxygenase 
and  ferritin  proteins  eventuates (Fig. 2C), consistent  with  the 
hypothesis  that  the  protective effect of hemin  preincubation 
might reflect induction of one  or  both of these  substances. 
A Hemin 10 HM 
0 l h  4h 8h 20h 
Heme 
Oxygenase - 
B 
I-Ferritin - I, I, .) I) 
C 
-1 r 790 
TIYE (hour) 
FIG. 2. Hemin induction of PAEC heme oxygenase  and  fer- 
ritin. A, for heme oxygenase mRNA  analysis,  endothelial cells were 
treated with hemin (10 PM) in 10 ml of DMEM for 60 min, and 10 
ml  of culture medium  was then replaced. At  the indicated  time,  RNA 
was  isolated, electrophoresed,  blotted,  and hybridized to a RYP-labeled 
heme oxygenase cDNA probe. B, L ferritin mRNA analysis was 
performed after the same treatment of endothelial cells using a 
ferritin cDNA probe. C, heme oxygenase activity  (open circles) and 
ferritin  protein (closed circles) were  measured in  PAEC  treated  as in 
panel A and measured as described under  “Experimental Procedures.” 
Results  represent  mean ? S.E. of a t  least  three  experiments done in 
duplicate. New synthesis of both H and L ferritin subunits was 
induced by hemin as measured by ferritin  immunoprecipitation using 
[:’‘S]methionine-labeled cells (not  shown). 
That ferritin,  rather  than heme  oxygenase, is  the  ultimate 
protectant  is implied by data  in  Table I. We developed two 
experimental  conditions  that induced endothelial  ferritin  but 
not  heme oxygenase; both were cytoprotective. Thus,  prein- 
cubation of endothelial cells with a cell permeant Fe-PIH 
chelate or with a combination of hemin and tin mesopor- 
phyrin IX (an  inhibitor of heme  oxygenase) causes  substantial 
increases in intracellular ferritin without any increment in 
heme oxygenase  activity. In  both of these cases, an associated 
marked protection against subsequent hemin + H202 chal- 
lenge is noted. However, under converse circumstances (if 
cells were incubated with hemin + deferoxamine or with 
sodium arsenite) high levels of heme oxygenase, but not 
ferritin, accrue; no  associated  protection  against  later chal- 
lenge by hemin  and H202 is afforded. Not surprisingly,  inhi- 
bition of all new protein  synthesis  with cycloheximide also 
ablates  induction of this  protective mechanism. In  studies not 
shown,  addition of the  potent heme-binding protein, hemo- 
pexin, to  our  system  prevented  both  heme  uptake by endothe- 
lial  cells and  subsequent  ferritin  synthesis;  no cytoprotection 
was  induced under  these  circumstances. 
Evidence  favoring a critical  antioxidant role for  intracellu- 
lar  ferritin  remains,  nonetheless,  circumstantial. Cells prein- 
cubated  with  heme  and  other  protective compounds  might be 
making numerous, subtle and unsuspected adjustments in- 
volving neither heme  oxygenase nor  ferritin synthesis. There- 
fore, to  examine  the consequences of elevated intracellular 
ferritin per se, we directly loaded preformed ferritin into 
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TABLE I 
Heme  oxygenase  and  ferritin  inductions  in  porcine aortic  endothelial cells by  hemin:  effect on hemin  plus  hydrogen  peroxide-mediated 
free radical injury 
Sn-meso-P. tin mesoooruhvrin  IX:  CHX,  cvcloheximide, DF. deferoxamine  mesvlate. 
Endothelial cell induction“ Heme oxygenase enzyme  activity Ferritin  content 
Hemin + 
H20yb 
cvtotoxicitv 
pmol bilirubin formedl 
mg cell protein160  rnin ng/rng cell protein % ”Cr release 
Buffer 13.7 f 1.6‘ 58.3 k 8.0 61.90 & 1.5 
Hemin (10 pM) 275.0 k 28.6 574.4 k 18.4 0.54 f 0.9 
Fe-PIH (100-200 p ~ )  15.0 t 1.6 431.5 t 27.3 10.20 f 4.3 
Hemin + Sn-meso-P (25 p M )  6.7 & 2.9 522.6 k 17.6 0.88 f 1.1 
Hemin + DF (1 mM) 343.3 f 41.2 36.2 k 2.4 58.50 f 3.9 
Sodium arsenite (50 pM) 77.5 f 5.2 68.9 f 6.3 59.50 f 1.3 
Hemin + CHX (10 Ng/ml) 10.0 k 1.36 28.4 k 2.3 58.89 k 2.3 
” Endothelial cells were induced with hemin  or other  reagents  as  described  under  “Experimental  Procedures.” At the time  points of the 
H,O,-mediated  cytotoxicity  assays endothelial cell  heme  oxygenase activities  and  ferritin contents were also determined. 
For  PAEC cytotoxicity, 100 p~ H,O,  was  used after the  60-min 5 p~ hemin sensitization period  as  described in Fig. 1B. 
‘ The  results  represent mean f S.E. of at least  three  experiments  done in duplicate. 
TABLE I1 
Ferritin  induction  and  ferritin  loading of porcine  aortic  endothelial 
cells  influence  endothelial cell sensitiuity  to  hemin catalyzed  hydrogen 
peroxide  toxicity 
Endothelial cell treatment”  Ferritin  content HzO,h 
Hemin + 
cytotoxicity 
ng/rng cell protein % ”Cr release 
Huffer 58.3 k 8.0‘ 61.9 f 1.5 
Hemin ( p M )  
1 .o 146.7 f 35.8 51.1 f 4.6 
2.5 282.0 t- 56.4 37.7 f 5.0 
5.0 400.0 f 18.0 19.0 f 3.6 
10.0 574.4 f 18.4 0.54 f 0.9 
0.1 180.0 f 58.8 65.4 f 3.7 
0.5 499.4 f 64.7 46.8 f 3.0 
1 .o 1,139.0 t- 129.0 22.8 k 2.3 
2.0 1,879.0 ir 352.0 0.45 f 1.0 
Horse  apoferritin (mg/ml) 
Recombinant human  heavy 
chain  ferritin 
Wild type 1.0 mg/ml 1,193.0 & 154.0 23.4 t- 2.9 
Mutant (222) 1.0 mg/ml 1,012.0 t- 112.5 68.3 f 2.4 
“ PAECs  were treated with hemin or apoferritins  as  describedunder 
“Experimental  Procedures.” At the time  points of the H202-mediated 
cytotoxicity  assays  endothelial cell ferritin contents were also deter- 
mined. 
5 p~ Hemin sensitization  and 100 p M  H,O, injury of PAECs were 
carried out as described in Fig. 1B. 
’ The  results  represent mean f S.E. of at least three  experiments 
done in duplicate  except at recombinant human ferritin treatments 
which were done  two  times in duplicate. 
cultured  endothelial cells. This was accomplished  via simple 
incubation of the cells with increasing  concentrations of ex- 
ogenous apoferritin. Diverse cells have  been shown  to  pino- 
cytose  extracellular  ferritin (34), and  as  validated by chemical 
and  immunofluorescent  assays,  our  cultured  endothelial cells 
also  accumulate  substantial  ferritin  during  such  incubations 
(see below). As shown in  the middle portion of Table 11, these 
ferritin-loaded cells become resistant, in a dose-responsive 
fashion,  to  the  oxidant  stress imposed by the  combination of 
H202 + heme or to   H202 alone  (not  shown). Accompanying 
this resistance was a parallel reduction in the incubated 
endothelial cells of lipid peroxidation  products,  measured  as 
thiobarbiturate-reactive material ( 5 ) .  For  instance,  in  control 
heme/H202-exposed cells undergoing approximately 60% cy- 
tolysis, thiobarbiturate-reactive material  accumulates (2.3 f 
0.1 nmol/mg of cell protein); conversely, in  cytolysis-resistant, 
ferritin-enriched cells thiobarbiturate-reactive material  is 
:i 30 20 10 
1 0  1 0 0  1 0 0 0  1 0 0 0 0  
ENDOTHELIAL CELL FERRITIN 
( n g h g  cell proteln) 
FIG. 3. Endothelial cell ferritin inversely correlates with 
HzOz/hemin-mediated cytotoxicity. Ferritin was determined as 
described under “Experimental Procedures” in PAEC whose levels 
were either  increased by exposure to hemin, Fe-PIH, or apoferritin 
at varying  concentrations (Table 11)  or  decreased  with  cycloheximide 
or deferoxamine (Table I).  H20, endothelial  cytotoxicity was meas- 
ured after  sensitization with  hemin as in  Fig. 1B. Each  point  repre- 
sents at least  two experiments done in duplicate.  The closed squares 
represent cells loaded  with exogenous apoferritin. 
negligible following heme/H202 exposure (0.2 k 0.1 nmol/mg 
of cell protein). Protection from heme/H202 assault is af- 
forded specifically by apoferritin,  and  endothelial cells prein- 
cubated  with  other  proteins  (including  apotransferrin, apolac- 
toferrin,  and  albumin) fail to  exhibit  any increase  in resistance 
to H202 or heme + H202 (results  not  shown). 
Indeed,  under various experimental  conditions a close in- 
verse linear  correlation ( r  - -0.97) between  induced intracel- 
lular  ferritin  content  and  the susceptibility of endothelial cells 
to  oxidant challenge can be appreciated (Fig. 3). Ferritin  has 
ferroxidase activity located on  the H but  not  the L subunit 
(18). This activity catalyzes the oxidation of ferrous iron 
under aerobic conditions  to ferric  iron to allow intracellular 
iron  storage  in biological systems.  In  our  studies of endothelial 
cells, the  protection provided by ferritin  is evidently attrib- 
utable  either  to  iron  storage  and/or  to  the  intrinsic fer oxidase 
activity of the H chain. This is supported by experiments 
shown in the bottom portion of Table I1 in which human 
recombinant wild type or mutant H chain  ferritin (18) was 
loaded into  cultured  endothelium. As expected, the wild type 
ferritin H chain  protected  as well as  intact  ferritin. However, 
the  mutant H chain, which  lacks both ferroxidase activity  and 
iron storage capability,  fails to provide any  protection. 
By immunofluorescent assay ferritin induced in human 
umbilical  vein endothelial cells by exposure to  hemin is found 
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widely distributed  in  the cytoplasm in a  finely granular  fash- 
ion in almost every cell (Fig. 4B); this contrasts with the 
sparse  and  sporadic  distribution  noted  in  control  endothelial 
cells (Fig. 4A). When exogenous apoferritin  is  added,  nearly 
every cell contains  ferritin  but  in a coarser  granular  pattern 
(Fig. 4C). Fig. 4 0  demonstrates morphologically that hemin- 
induced  ferritin  synthesis  is  inhibited by  deferoxamine, cor- 
roborating  the  fluorometric  enzyme  immunoassay  results  and 
cytotoxicity  data  presented  in  Table I. In  nonpermeabilized 
(3.6% paraformaldehyde-fixed) endothelial cells, no immu- 
noreactive ferritin was noted on the cell surface of heme- 
treated cells, whereas there  was  slight  and  variable  surface 
staining of endothelial cells  exposed to apoferritin  (data  not 
shown).  This suggests that  the  ferritin complex is  primarily 
localized intracellularly. 
DISCUSSION 
Ferritin  has generally  been thought  to  function as a “hou- 
sekeeper”  storage  protein (6) which can release iron  required 
for cellular proliferation (e.g. for ribonucleotide reductase) 
and  metabolic renewal (e.g. for cytochrome synthesis). Al- 
though some studies  have suggested that  ferritin  can  amplify 
oxidative  phenomena (7, 8), evidence can  also be marshalled 
to suggest that ferritin may play a protective role against 
toxic effects of iron overload in cells. For  instance, rat liver 
nuclei from iron-intoxicated animals excessively transcribe 
ferritin  (L  subunit)  mRNA  as  compared  with  control  animal 
nuclei (29). We believe the present studies more directly 
support  this  latter  notion by demonstrating a  dose-responsive 
cytoprotective, antioxidant effect of ferritin in iron-loaded 
cells (Fig. 3). Further  correlative  support  may  derive  from  the 
time-dependent dichotomous effects of heme exposure on 
endothelial cells. Thus,  heme amplifies oxidant-mediated cy- 
totoxicity  during brief (2 h) exposure, yet  markedly  protects 
oxidant-exposed  target cells if provided for longer durations. 
These  results  correlate  with  the 1-2-h time lag that is  then 
followed by rapid  synthesis of ferritin  in  endothelium exposed 
to heme (Fig. 2C). Finally,  the likelihood that  ferritin per se 
is  the  critical  cytoprotectant  in  our  study  is  buttressed by its 
significant  (albeit less potent) efficacy even when exogenously 
added  to  cultured cells (compare solid and open symbols, Fig. 
3). 
Usually cells take up iron in a highly regulated fashion 
dependent on transferrin binding and cellular transferrin 
receptor modulation; however, cells can  evidently  also incor- 
porate iron by transferrin receptor-independent pathways 
C 
FIG. 4. Ferritin immunofluorescence in human umbilical 
vein  endothelial  cells. A, control; H, hemin (10 p ~ )  induction for 
16 h; C, exogenous apoferritin-loaded for 16 h; and 11, hemin (10 PM) 
plus deferoxamine (1 mM) induction for 16 h, as described under 
“Experimental Procedures” (magnification for all panels: 400 x). 
with  potential  deleterious outcome. For example, studies by 
others which  seem particularly  relevant to  the  present work 
have  demonstrated  that  the  uptake of heme with  resultant 
iron loading can occur in  cultured cell lines via specific non- 
transferrin  receptors (35). Perhaps  as a countermeasure,  di- 
verse species possess avid heme-binding proteins, such as 
hemopexin,  which  efficiently inhibit cellular  heme uptake  and 
heme-catalyzed oxidation  reactions (36,37). Moreover, many 
uni-  and  multicellular  organisms  also  appear purposefully to 
destroy free intracellular heme by enzymatic means. For 
instance,  heme oxygenase, a ubiquitous enzyme which opens 
the porphyrin ring and releases heme iron, is induced in 
several tissues by oxidant  stress  (and by free heme) (27,  38). 
In  fact,  it  has been  suggested that  the  other  product of heme 
oxygenase activity,  bilirubin, may  itself  be an  important  an- 
tioxidant.  Nevertheless,  the  salutary  effects of enhanced heme 
oxygenase activity  are  not  intuitively obvious. Although ca- 
tabolism of heme  may  rid  the cell of a membrane-permeant 
form of iron, the resultant non-heme iron would seem to 
represent a potential  hazard  unless  sequestered  in some way. 
Indeed,  the  present  studies  demonstrate  that  heme oxyg nase 
activity,  unlike  ferritin, does not  correlate  with cytoprotec- 
tion.  Instead, we suggest that  heme oxygenase serves mainly 
to provide  free intracellular  iron  from  added heme; this iron, 
in  turn  (unless  chelated by  deferoxamine; Table  I), drives the 
synthesis of ferritin, which is likely the  proximate  protectant 
against  oxidant damage.  Alternatively,  heme  itself  might en- 
hance  ferritin  synthesis  directly by increasing RNA transla- 
tion as recently shown by Lin  and co-workers (39). 
The  protective  effects of elevated  intracellular  ferritin  re- 
ported  herein  presumably  add to those of antioxidant enzymes 
such as catalase,  glutathione-related enzymes, and superoxide 
dismutase. Induction of these enzymes has been linked by 
others  to  subsequent  protection of cells from  oxidant  chal- 
lenge. In  that regard, in  our  hands hemin-exposed endothe- 
lium  does not  increase  its  catalase  or  glutathione peroxidase 
levels over 16 h (data  not  shown). 
Our  results  using  the  recombinant  mutant 222 demonstrate 
that ferritin’s potent antioxidation efficiency probably de- 
pends  on  one or both of its  unique molecular characteristics: 
namely, its high sequestering  capacity  for inorganic iron  and 
the ferroxidase activity of its H chain, both lacking in  the 
mutant.  Presumably  the  latter  prevents significant  accumu- 
lation of cellular Fez+, the ultimate catalyst of oxidative 
damage. New H chain recombinants will soon be available 
which should allow further dissection of molecular character- 
istics  critical  for  cytoprotection.  Thus,  endothelial  protection 
studies  are  planned which will utilize a mutant  that  manifests 
ferroxidase activity  but which cannot  incorporate  iron because 
of deletion of 22 amino  acids forming the hydrophobic channel 
of the molecule (40). 
It is becoming  increasingly clear  that  the susceptibility of 
eukaryotic and prokaryotic cells to oxidants is powerfully 
influenced (if not  dictated) by levels of reactive intracellular 
iron. Relatively iron-poor cells (and many inherently iron- 
poor organisms)  are highly resistant  to  oxidants  and  oxidant 
drugs (41). By contrast, cells containing excess iron (for 
instance, bacteria grown in iron-rich conditions or malaria 
parasites which generate  ferruginous  deposits from digestion 
of host red cell hemoglobin) are easily  destroyed by oxidants 
(1, 42). Germane  to  the  potential role of endothelial oxidant 
damage  in  atherogenesis  are  recent observations:  namely, that 
vessel wall cells  from atherosclerotic lesions are  remarkably 
iron-rich as compared  with neighboring  unaffected vascular 
tissue from the  same individuals (43). 
We suggest from  our  studies  that  under iron-loading  con- 
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ditions  the facile synthesis of ferritin,  an  intracellular  protein 
present  in species ranging  from  bacteria  to  humans, may be 
a n  important  mechanism  to  control reactive iron  and  thereby 
suppress  oxidant damage. Studies  in  press (44) further  sup- 
port this  notion.  We  have  shown  that  oxidant-mediated  and 
universally fatal  renal  failure  results  from rhabdomyolysis in 
glycerol-injected rats  but  not if animals  are  preinfused  with 
hemoglobin. Protection  parallels  the  induction of high levels 
of renal ferritin; conversely, ablating this response with a 
competitive  inhibitor of heme oxygenase, tin  protoporphyrin, 
markedly accelerates kidney dysfunction in these animals 
(44). 
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